Upgrade to SI Premium - Free Trial

Amarin (AMRN) Could Get FDA Catalysts By Year-End, Says Leerink Swann

August 9, 2013 10:59 AM
Leerink Swann maintained an Outperform rating on Amarin Corporation (NASDAQ: AMRN) and adjusted its price target to $18.00 (from $20.00) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)


Analyst Comments Analyst EPS View FDA

Next Articles